Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Adaptimmune Raises USD104 Million in Series A Venture Financing 12
Private Equity 14
Adaptimmune Therapeutics Raises USD100 Million in ADS 14
Partnerships 15
Adaptimmune Therapeutics Enters into Co-development Agreement with Bellicum Pharma 15
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 16
Adaptimmune Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 17
Licensing Agreements 18
Adaptimmune Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 18
Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 19
GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 20
GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 22
Adaptimmune Enters Into Licensing Agreement With Life Technologies 23
Equity Offering 24
Adaptimmune Therapeutics Raises USD42 Million in Private Placement of American Depositary Shares 24
Adaptimmune Therapeutics Raises USD65.9 Million in Public Offering of American Depositary Shares 25
Adaptimmune Therapeutics to Raise up to USD75 Million in Public Offering of American Depositary Shares 26
Adaptimmune Therapeutics Raises USD191.2 Million in IPO of American Depositary Shares 27
Adaptimmune Therapeutics Plc – Key Competitors 29
Adaptimmune Therapeutics Plc – Key Employees 30
Adaptimmune Therapeutics Plc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
Nov 06, 2017: Adaptimmune marks Official Opening of U.K. Headquarters 32
Financial Announcements 33
Mar 15, 2018: Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update 33
Nov 02, 2017: Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates 36
Aug 03, 2017: Adaptimmune Reports Second Quarter 2017 Financial Results 37
May 10, 2017: Adaptimmune Reports First Quarter 2017 Financial Results 39
Mar 13, 2017: Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results 40
Corporate Communications 42
Apr 12, 2018: Adaptimmune Announces Changes to Board of Directors 42
Mar 15, 2017: Adaptimmune Broadens Executive Team 43
Jan 09, 2017: Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development 44
Product News 45
11/10/2017: Adaptimmune Presents Study Design for Ongoing MAGE-A4 Clinical Trial at Society for Immunotherapy of Cancer Annual Meeting 45
08/15/2018: Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort 46
07/18/2018: Adaptimmune announces favorable review of safety from one billion cell dose cohort in MAGE-A10 SPEAR T-cell study and initiation of third dosing cohorts 47
06/04/2018: Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO 48
05/16/2018: Adaptimmune to Present Data from MAGE-A10 Study at ASCO Annual Meeting 49
01/08/2018: Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose 50
Product Approvals 51
Jan 09, 2017: Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors 51
Clinical Trials 52
Jun 04, 2018: Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells 52
Apr 16, 2018: Adaptimmune Presents Pre-clinical Data on MAGE-A10 SPEAR T-cells at AACR Annual Meeting 53
Apr 16, 2018: Adaptimmune Presents Pre-clinical Data on MAGE-A4 SPEAR T-cells at AACR Annual Meeting 54
Apr 06, 2018: Adaptimmune to Present Preclinical Data of MAGE-A10 SPEAR T-cells at AACR Annual Meeting 56
Apr 06, 2018: Adaptimmune to Present Preclinical Data of MAGE-A4 at AACR Annual Meeting 57
Nov 03, 2017: Adaptimmune to Present Update On MAGE-A4 Multi-tumor Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting 58
May 16, 2017: Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors 59
May 10, 2017: Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer 60
Other Significant Developments 61
Jan 08, 2018: Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adaptimmune Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adaptimmune Raises USD104 Million in Series A Venture Financing 12
Adaptimmune Therapeutics Raises USD100 Million in ADS 14
Adaptimmune Therapeutics Enters into Co-development Agreement with Bellicum Pharma 15
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 16
Adaptimmune Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 17
Adaptimmune Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 18
Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 19
GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 20
GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 22
Adaptimmune Enters Into Licensing Agreement With Life Technologies 23
Adaptimmune Therapeutics Raises USD42 Million in Private Placement of American Depositary Shares 24
Adaptimmune Therapeutics Raises USD65.9 Million in Public Offering of American Depositary Shares 25
Adaptimmune Therapeutics to Raise up to USD75 Million in Public Offering of American Depositary Shares 26
Adaptimmune Therapeutics Raises USD191.2 Million in IPO of American Depositary Shares 27
Adaptimmune Therapeutics Plc, Key Competitors 29
Adaptimmune Therapeutics Plc, Key Employees 30
Adaptimmune Therapeutics Plc, Other Locations 31
Adaptimmune Therapeutics Plc, Subsidiaries 31
List of Figures
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adaptimmune Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9